Premium
Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity
Author(s) -
Shi Youwu,
Liu Peng,
Zhou Shengyu,
Yang Jianliang,
Han Xiaohong,
He Xiaohui,
Zhang Changgong,
Gui Lin,
Qin Yan,
Yang Sheng,
Zhao Liya,
Yao Jiarui,
Jia Bo,
Zhang Shuxiang,
Sun Yan,
Shi Yuankai
Publication year - 2017
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.12610
Subject(s) - carmustine , etoposide , cytarabine , medicine , melphalan , cyclophosphamide , chemotherapy , lymphoma , hematopoietic stem cell transplantation , transplantation , mucositis , oncology , surgery
Aim Limited data are available to guide the choice of conditioning regimen before autologous hematopoietic stem cell transplantation (AHSCT) for patients with lymphoma. Methods We analyzed 129 non‐Hodgkin lymphoma patients who underwent AHSCT from 1996 to 2013 using the most common regimens: CBV (cyclophosphamide, carmustine and etoposide; n = 16), BEAM (carmustine, etoposide, cytarabine and melphalan; n = 36) and BEAC (carmustine, etoposide, cytarabine and cyclophosphamide; n = 77). Results At a median follow‐up of 42.5 months, the estimated 5‐year overall survival for the CBV, BEAM and BEAC groups was 68.8%, 77.8% and 81.8%, respectively ( P = 0.584). The estimated 5‐year progression‐free survival in the CBV group (43.8%) was relatively inferior to the BEAM (66.7%) and BEAC (67.5%) groups, but the differences were not significant ( P = 0.403). Grade 2 or higher mucositis, diarrhea and fever were relatively more common in the BEAM group ( P < 0.05). No differences were observed in the time to hematopoietic recovery and the duration of hospitalization. The amount of transfused platelet was significantly less in the CBV. Conclusion CBV, BEAM and BEAC regimens are all optional high‐dose chemotherapy before AHSCT for NHL patients.